Abstract: An instrument for implanting an elastically foldable intraocular lens in an eye is described. The instrument comprises a barrel having proximal and distal ends and a nozzle having a slender ocular insertion end region sized for insertion through an ocular incision no greater than about 3.7 mm., the nozzle being attached to the distal end of the nozzle. The barrel includes an intraocular lens holding chamber upstream of the nozzle. First and second shield elements are disposed inside along opposite side regions of the nozzle, each of the shield elements having an elastically deformable protective shield region disposed in the nozzle in an elastically deformed state.

Abstract: An intraocular lens (IOL) insertion system, cartridge and/or combination cartridge and folding member that facilitates multiply folding an IOL within a load chamber of the cartridge prior to insertion in an eye. In the system embodiment, a folding member is provided in a handpiece that interacts with the cartridge to multiply fold the IOL therewithin. Alternatively, the cartridge may incorporate the folding member in its structure, or a separate folding member that interacts with the cartridge may be provided in a combination. The folding member may be a planar element that extends through a slot in the wall of the load chamber to displace a midportion of the IOL away from the inner wall of the load chamber. Desirably, the multiply folded configuration that results is an M-shape or a W-shape, depending on orientation. The cartridge may further include structure that retains the multiply folded configuration of the IOL as it passes through an injection tube and into the eye.

Abstract: An intraocular lens (IOL) insertion apparatus including a cartridge with an IOL-receiving chamber, a handpiece into which the cartridge is loaded, and a plunger rod that extends through a lumen in the cartridge to reliably engage the IOL therein. The chamber is stepped in one section to cause the IOL positioned therein to assume a complex curve. A lip or projection on the plunger rod is aligned with the complex curve and intersects the IOL to reliably engage the IOL across its thickness. The cartridge may be a folding type with a pair of arcuate walls and extension wings joined at a living hinge. The stepped section of the chamber may coincide with the location of the hinge.

Abstract: The invention provides for the use of a botulinum toxin to treat cerebral palsy in juvenile patients by transdermal administration of the botulinum toxin. The juvenile patients are preferably juveniles of up to 6 years in age.

Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a Clostridial toxin, such as a botulinum toxin, to the thyroid gland of a patient.

Abstract: A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na+ chanels, and the lethal elevation of cell Ca2+ due to reversal of the Na+/Ca2+ exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na+ channels in retinal ganglion cells in order to limit Na+/Ca+ exchange in the retinal ganglion cells and prevent buildup of the Ca2+ level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve.

Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.

Abstract: A flexible tip I/A tip assembly includes an elongated sleeve for protecting an eye capsule wound through which the sleeve is inserted and for containing irrigation fluid. The sleeve includes a lumen therethrough and a nipple for removably coupling the elongated sleeve to a handle by elastomeric contact therewith. A retractor with a worm is disposed within the sleeve for transferring aspiration in any angle of the eye capsule. The sleeve and the retractor are held in operational relationship with the handpiece by a nipple which, due to its transparency, enables visual adjustment, alignment, installation and confirmation of the operative relationship therebetween.

Abstract: Methods for treating an injured muscle by local administration of a neurotoxin, such as a botulinum toxin, to promote healing and/or to reduce the pain associated with an injured muscle.

Abstract: A method for treating a mammary gland disorder, including hyperplasic, hypertonic, cystic and/or neoplastic mammary gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted breast tissue.

Abstract: A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na+ channels, and the lethal elevation of cell Ca2+ due to reversal of the Na+/Ca2+ exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na+ channels in retinal ganglion cells in order to limit Na+/Ca+ exchange in the retinal ganglion cells and prevent buildup of the Ca2+ level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve.

Abstract: The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into a sympathetic ganglion, thereby reducing an inhibitory effect upon insulin secretion.

Abstract: Methods for treating hyperhidrosis is disclosed herein. In one embodiment, the method includes a step of administering a neurotoxin to a skin area to alleviate excessive sweating. In another embodiment, the method employs a needleless injector to affect the administration of a neurotoxin, for example botulinum toxin type A.

Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.

Abstract: A method and composition for treating a patient suffering from an excessive mucus secretion includes administration to the patient of a therapeutically effective amount of a botulinum toxin type A, B, C, D, E, F and/or G.

Abstract: Compounds of Formula 1 1

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a 3, 7 or 3 and 7 thia or oxa prostanoic acid derivative.

Abstract: A method for increasing or decreasing parasympathetic/cholinergic/ciliary tonic contraction in order to restore the resting portion of the eye and allow normal positive and negative accommodation includes administering to a myopic or hyperopic presbyope.

Abstract: An iris-supported intraocular lens having an optic portion and a plurality of fixation members coupled thereto. Each fixation member has a pair of pincer arms that separate outward of the optic and converge toward one another at aligned end tips. One or both of the end tips are covered with a soft sleeve or cap. The IOL is fixed in the anterior chamber of the eye by pinching the iris tissue between the end tips of each pair of pincer arms. The soft sleeves eliminate damage to the iris tissue.

Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.